Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology PressReach · Dec 5, 2022
Tonix Pharmaceuticals Announces Collaboration with Boston Children's Hospital to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in Animals PressReach · Dec 5, 2022
Cosmos Health Provides a Summary Regarding Recent Share Activity and Reiterates its Belief and Commitment to the Financial Strength and the Growth and Profitability of the Company PressReach · Dec 3, 2022
Quest Diagnostics Awarded Laboratory Stewardship Platform and Services Agreement with Premier, Inc. PressReach · Dec 2, 2022
Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference PressReach · Dec 2, 2022
Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies(TM) (HSB-1940) against PD-1, by combining Quatramers(TM) with OmniAb's Picobodies(TM), via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets PressReach · Dec 2, 2022
Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022 PressReach · Dec 2, 2022
Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference PressReach · Dec 2, 2022
AbbVie Announces Provincial Reimbursement for RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan PressReach · Dec 1, 2022
Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation PressReach · Dec 1, 2022